We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Identifies Mortality Risk for Trauma Patients

By LabMedica International staff writers
Posted on 04 Feb 2013
A simple, inexpensive blood test performed on trauma patients upon admission can help doctors easily identify patients at greatest risk of death. More...


A computerized tool that combines factors like age, gender, and common blood tests known as the complete blood count (CBC) and the basic metabolic profile (BMP) can determine an individual's mortality risk is now available to physicians.

Scientists at the Intermountain Medical Center (Salt Lake City, UT, USA) studied 9,538 patients and discovered that some trauma patients are far more likely to die than others were, regardless of the severity of their original injuries. The Intermountain Risk Score is a computerized tool and has been helpful in evaluating individuals with medical problems like heart failure or chronic pulmonary disease. The benefit of the tool had not been tested for trauma patients hospitalized due to an accident or traumatic injury, rather than an underlying condition.

The Intermountain Medical Center used the tool to categorize patients according to high, moderate, and low risk levels. Some surprising findings emerged as high-risk men were nearly 58 times more likely to die within a year than low-risk men were. Men with a moderate risk were nearly 13 times more likely to die than those with low risk. High-risk women were 19 times more likely to die within a year than low-risk women were, and women with moderate risk were five times more likely to die than those with low risk.

Sarah Majercik, MD, an Intermountain Medical Center surgeon, said, "As surgeons, we don't often use all of the CBC results in evaluating a patient who needs surgery for a bleeding spleen or after a motor vehicle accident. There are certain values, such as hemoglobin, hematocrit, and platelets that we scrutinize closely as part of good clinical care, but then other parts, such as the red blood cell distribution width (RDW) that we pay no attention to at all in the acute setting. These factors are generally overlooked, even though they are part of the CBC that every trauma patient gets when he or she arrives in the emergency room." The study was presented on January 18, 2013, at the 27th annual Scientific Session of the Eastern Association for the Surgery of Trauma held in Phoenix (AZ, USA).

Related Links:
Intermountain Medical Center


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Urine Analyzer
respons® UDS100
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.